NCT02252731View on ClinicalTrials.gov

A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Pharmacokinetics of FG-4592Healthy Subjects
Interventions
DRUG

Warfarin

Oral

DRUG

FG-4592

Oral

Trial Locations (1)

14050

Parexel International GmbH, Berlin

Sponsors

Collaborators (1)

FibroGen
All Listed Sponsors
collaborator

FibroGen

INDUSTRY

lead

Astellas Pharma Europe B.V.

INDUSTRY